Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
about
Emerging and future therapies for hemophiliaPredicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Acquired hemophilia A: emerging treatment options.Acquired hemophilia A: a review of recent data and new therapeutic options.Novel therapeutic approaches for haemophilia.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.New products for the treatment of haemophilia.Safety surveillance in haemophilia and allied disorders.Emerging drugs for the treatment of hemophilia A and B.Extended half-life clotting factor concentrates: results from published clinical trials.Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.Alternative therapies for the management of inhibitors.A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.Non-factor replacement therapy for haemophilia: a current update.The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody.The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A
P2860
Q26781143-CF7AA102-1FFF-4897-86C0-F9B012D674AEQ31091923-150C81B7-479F-4E8D-8383-E887C2293F9EQ34503723-BBDC60BD-3353-4CC6-8113-015C469668A7Q35605896-AE76B348-54C7-47B2-BC5F-4A43B872D1F4Q36356147-BAA178FC-69A0-49C9-B7D9-F5B0E4A936BDQ38293116-D5678653-35D5-4CA6-89E4-1669600D036CQ38574414-DA965DA2-5C8D-453C-9CCF-F16BB0E86E6EQ38604626-330CA262-7542-43D7-8F1B-A7286AA3B5F1Q38784133-945F3492-EB0D-4BE1-8E36-71BE9E348032Q38933707-57D68A8D-7243-4D07-96D7-C2E72A9FF6C5Q39609294-C9E38118-5C13-441E-87B0-E3FCDD3290C5Q42076342-A4A7AA51-7106-4A3F-95CA-151E4A7EF903Q45856195-A932ECE4-194B-4CC2-BB9D-26856EBFEE66Q45875541-F982AE3C-6A0D-46D9-8B89-12E419EB7592Q52362938-5E546768-0D5B-4592-A897-6EACD5968CB4Q55211396-DDCC344D-2FAB-48AF-BADC-A880900B3B26Q57816367-46BF2D82-7181-4A5F-AB9D-ED5E31AD101C
P2860
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Anti-factor IXa/X bispecific a ...... odel of acquired hemophilia A.
@en
type
label
Anti-factor IXa/X bispecific a ...... odel of acquired hemophilia A.
@en
prefLabel
Anti-factor IXa/X bispecific a ...... odel of acquired hemophilia A.
@en
P2093
P2860
P50
P921
P1433
P1476
Anti-factor IXa/X bispecific a ...... model of acquired hemophilia A
@en
P2093
Akihisa Sakamoto
Atsushi Muto
Kazutaka Yoshihashi
Keiji Nogami
Kenji Adachi
Kunihiro Hattori
Midori Shima
Minako Takeda
Taichi Kuramochi
Takehisa Kitazawa
P2860
P304
P356
10.1182/BLOOD-2014-07-585737
P407
P577
2014-10-01T00:00:00Z